Emprise Bank Makes New Investment in The Clorox Company (NYSE:CLX)

Emprise Bank purchased a new position in shares of The Clorox Company (NYSE:CLXFree Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,197 shares of the company’s stock, valued at approximately $336,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC lifted its stake in Clorox by 0.5% during the fourth quarter. CIBC Private Wealth Group LLC now owns 13,900 shares of the company’s stock worth $1,982,000 after purchasing an additional 66 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services increased its holdings in shares of Clorox by 3.2% in the fourth quarter. First National Bank of Mount Dora Trust Investment Services now owns 2,257 shares of the company’s stock worth $322,000 after buying an additional 71 shares during the period. Modera Wealth Management LLC increased its holdings in shares of Clorox by 1.4% in the third quarter. Modera Wealth Management LLC now owns 5,130 shares of the company’s stock worth $672,000 after buying an additional 71 shares during the period. Czech National Bank increased its holdings in shares of Clorox by 0.3% in the fourth quarter. Czech National Bank now owns 21,718 shares of the company’s stock worth $3,097,000 after buying an additional 71 shares during the period. Finally, Global Retirement Partners LLC increased its holdings in shares of Clorox by 7.2% in the fourth quarter. Global Retirement Partners LLC now owns 1,089 shares of the company’s stock worth $156,000 after buying an additional 73 shares during the period. Institutional investors own 78.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on CLX shares. DA Davidson reiterated a “neutral” rating and issued a $162.00 price objective on shares of Clorox in a report on Wednesday, April 17th. Barclays reduced their price target on Clorox from $136.00 to $132.00 and set an “underweight” rating on the stock in a report on Thursday, May 2nd. Evercore ISI reduced their price target on Clorox from $145.00 to $142.00 and set an “underperform” rating on the stock in a report on Wednesday, May 1st. Morgan Stanley restated an “equal weight” rating and set a $160.00 price target on shares of Clorox in a report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. reduced their price target on Clorox from $159.00 to $158.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Four analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $146.43.

Read Our Latest Analysis on Clorox

Clorox Stock Up 0.5 %

Clorox stock traded up $0.67 during trading hours on Wednesday, hitting $138.63. 1,155,326 shares of the stock traded hands, compared to its average volume of 1,045,467. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 9.73. The firm’s 50-day moving average price is $137.91 and its two-hundred day moving average price is $144.11. The Clorox Company has a one year low of $114.68 and a one year high of $169.14. The company has a market cap of $17.22 billion, a PE ratio of 71.83, a PEG ratio of 2.24 and a beta of 0.39.

Clorox (NYSE:CLXGet Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.38. Clorox had a return on equity of 302.49% and a net margin of 3.33%. The firm had revenue of $1.81 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the firm posted $1.51 EPS. The business’s revenue for the quarter was down 5.3% compared to the same quarter last year. On average, research analysts forecast that The Clorox Company will post 5.84 EPS for the current year.

Clorox Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Featured Articles

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.